Tag: aspirin

1. 12-months after randomization, the de-escalation group met the criteria for superiority (p=0.0001) with respect to the composite primary outcome of cardiovascular mortality, myocardial infarction, stroke, or bleeding. 2. Type 2, 3, or 5 bleeding was significantly less frequent in the clopidogrel group (3.0%) compared to ticagrelor group (5.6%). Evidence Rating...

1. Risk of cardiovascular death, myocardial infarction, stroke, and revascularization was lower in the fixed-dose combination pill group compared to control. 2. Fixed-dose combination strategies with aspirin resulted in greater reductions in mortality compared to without aspirin. Evidence Rating Level: 1 (Excellent) Study Rundown: Cardiovascular disease is among the leading causes of...

1. Daily low-dose aspirin use during pregnancy in individuals at increased risk for preeclampsia was associated with a lower risk of preeclampsia, preterm birth, small for gestational age/intrauterine growth restriction, and perinatal mortality. 2. Pooled data on the safety profile of low-dose aspirin use during pregnancy in the prevention of...

1. Clopidogrel monotherapy reduced long-term rates of all-cause mortality, non-fatal myocardial infarction, and stroke after drug-eluting stent placement compared with aspirin monotherapy. 2. The superiority of clopidogrel was seen for both thrombotic and bleeding endpoints and was consistent across demographic groups. Evidence Rating Level: 1 (Excellent)  Study Rundown: Patients who receive percutaneous...

1. Preventative aspirin was used uniformly by persons with diabetes across age groups, while in persons without diabetes it was used less in young seniors (60-69 and 70-79) and equally in those 80+, potentially outside of clinical recommendations. 2. Based on the results of this study and current guidelines, a...

1. Guided selection of antiplatelet therapy reduced rates of major adverse cardiovascular event rates compared to standard therapy. 2. Guided selection strategy was beneficial for both escalation and de-escalation of standard therapy, balancing patient-dependent ischemic and bleeding risks.  Evidence Rating Level: 1 (Excellent) Study Rundown: Patients who undergo percutaneous coronary intervention (PCI)...

1. In patients treated with direct oral anticoagulants (DOACs) for atrial fibrillation or venous thromboembolism (VTE), adding aspirin (ASA) was associated with increased bleeding events. 2. Adding ASA to DOAC treatment for patients with atrial fibrillation or VTE did not improve the incidence of thrombotic events. Evidence Rating Level: 2 (Good) Study Rundown: Aspirin...

1. Polypill plus aspirin treatment was shown to decrease the incidence of cardiovascular events compared to placebo in patients without cardiovascular disease. 2. Adverse events such as hypotension and dizziness were shown to be higher in the polypill-only group compared to the placebo group. Evidence Rating Level: 1 (Excellent) Study Rundown: Polypills combining...

1. In patients treated with direct oral anticoagulants (DOACs) for atrial fibrillation or venous thromboembolism (VTE), adding aspirin (ASA) was associated with increased bleeding events. 2. Adding ASA to DOAC treatment for patients with atrial fibrillation or VTE did not improve the incidence of thrombotic events. Evidence Rating Level: 2 (Good) Study...

1. Polypill plus aspirin treatment was shown to decrease the incidence of cardiovascular events compared to placebo in patients without cardiovascular disease. 2. Adverse events such as hypotension and dizziness were shown to be higher in the polypill-only group compared to the placebo group. Evidence Rating Level: 1 (Excellent) Study Rundown: Polypills...